Interview: Semis Supply Chain Logistics Discussion Dustin Ross Yisroel — 2026-05-08
Key Themes
Solution in search of a problem. Yisroel’s core critique was direct: Bliss and Dustin can articulate what they’re building and why it’s technically interesting, but haven’t yet made the leap to why a customer would buy it. His suction/vacuum cleaner/14-hours-saved analogy was the anchoring frame for the whole conversation — the team is currently selling “suction.”
Defense/compliance as the real wedge. Yisroel validated the China compliance angle, but only for customers who structurally need to know: DoD (zero tolerance for Chinese chips in fighter jets), Department of State (NVIDIA chip leakage), and defense primes (Lockheed, Northrop) who can use compliance certification as a competitive differentiator. Commercial semis players, by contrast, have a perverse incentive not to know.
Cost savings as alternative value prop. For non-defense commercial customers, the pitch flips entirely: compliance isn’t the hook, margin improvement is. If TBD can help companies navigate around expensive China-avoidance supply chain detours and save 2% on supply chain costs, that translates to ~1% margin improvement — language that resonates with CFOs.
Customer discovery methodology. Yisroel was emphatic about a two-call approach: first conversation is purely “we want to learn, what are your pain points” — no pitching. Return 1-2 months later with “I solved one of your pain points.” Pain points first, solutions second. Warm intros are essential; cold outreach rarely penetrates at senior levels.
Partnership shortcut. DefCon AI has a potential conflict of interest (pitching in-transit visibility to Pentagon themselves), but once a product exists, there’s a packaging opportunity — DefCon takes ~1% vs. the typical 23% contractor margin, offering a shortcut to government sales.
Notable Quotes
- “You’ve created the concept of suction… knock on somebody’s door and say ‘I’m going to give you back 14 hours a week’ — now you’re talking.”
- “If I know it’s going to China now I can’t sell it anymore. You’ve done nothing good for me.”
- “Stage three is when people start saying, ‘Brumer said this, so it must be right’ — and I find myself running around going ‘no, just because I said it doesn’t make it right.‘”
- On mythological Brumer: “I was unable to override the opinion of mythological Brumer.”
Surprises
- Pharma/GLP-1 supply chains emerged as a lateral pivot opportunity — Yisroel flagged companies in a “massive supply chain battle” for GLP-1 market share, with supply chain positioning directly tied to capturing revenue. This was entirely outside the team’s current thesis framing.
- Yisroel offered his cell number unprompted and said to text rather than calendar (6-month wait). Unusually direct access signal.
- Govini recently became a unicorn solving an adjacent China compliance problem focused on specific defense mission areas — validating the thesis but also flagging a live, well-funded incumbent to map.
Open Questions
- What specific pain points do defense primes (F-35 program-level) actually experience in China compliance today — manual processes, audit exposure, something else?
- Is the GLP-1 supply chain angle worth a dedicated discovery sprint, or a distraction from semis focus?
- What’s DefCon’s exact conflict of interest with Pentagon in-transit visibility — and does that gate or enable the partnership?
- How does Govini’s focus on specific mission areas (Next Gen ICBM) leave room for TBD in broader semis compliance?